This inventor holds 1 USPTO granted patent. Top assignee: Ono Pharmaceutical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: James N. Sanderson: Pharmaceutical Invention and KDM5 Research
Introduction
James N. Sanderson is an inventor associated with Saffron Walden, Great Britain, and Ono Pharmaceutical Co., Ltd. His recorded patent work concerns a compound with KDM5 inhibitory activity and its potential pharmaceutical uses.
Latest Patents
Sanderson is associated with one patent, titled “Compound Having KDM5 Inhibitory Activity and Pharmaceutical Use Thereof.” The patent describes a KDM5 inhibitor represented by a general formula, or a salt thereof. The disclosed compound is proposed for use in the prevention or treatment of cancer, Huntington’s disease, Alzheimer’s disease, and related conditions. The record lists 1 patent for Sanderson.
Career Highlights
The available information connects Sanderson’s patent activity with Ono Pharmaceutical Co., Ltd., a pharmaceutical company. His listed invention focuses on a potential therapeutic compound and its applications in disease treatment.
Collaborations
Akito Kakuuchi and Shuhei Umemura are identified as Sanderson’s coworkers. Their names are associated with the collaborative context of his pharmaceutical patent work.
Conclusion
James N. Sanderson’s recorded invention reflects research into KDM5 inhibition and possible pharmaceutical applications, including treatments for cancer and neurodegenerative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile